What is PATH EX?
PATH EX is a medical technology innovator dedicated to the development of advanced extracorporeal blood cleansing devices. The company's core technology is engineered to diagnose and treat sepsis by selectively filtering pathogens and endotoxins directly from the bloodstream. This approach represents a significant departure from traditional pharmacological interventions, offering a mechanical solution that can be deployed in critical care settings to mitigate the immediate risks associated with bacteremia. By targeting the root cause of systemic infection, PATH EX aims to improve patient outcomes in high-acuity environments where time-sensitive treatment is the primary determinant of survival.
How much funding has PATH EX raised?
PATH EX has raised a total of $5M across 1 funding round:
Other Financing Round
$5M
Other Financing Round (2025): $5M with participation from TMC Ventures, Fitz Gate Ventures, and IAG Capital Partners
Key Investors in PATH EX
TMC Ventures
TMC Ventures is a strategic investment firm that focuses on evidence-based health solutions and wellness innovations, providing both capital and industry expertise to high-growth medical ventures.
Fitz Gate Ventures
Fitz Gate Ventures is an early-stage venture capital firm specializing in deeptech startups, leveraging a proprietary community network to provide strategic advantages to its portfolio companies.
IAG Capital Partners
IAG Capital Partners is a venture capital firm that leads investment rounds from seed to Series C, providing essential financial support to innovative companies looking to scale their operations globally.
What's next for PATH EX?
With this major enterprise-level funding, PATH EX is well-positioned to scale its operational capabilities and deepen its clinical research initiatives. The strategic roadmap likely involves expanding the scope of its clinical trials to demonstrate the efficacy of its blood cleansing platform across broader patient demographics. Furthermore, the company is expected to leverage its investor network to navigate complex regulatory landscapes and prepare for commercialization. As the firm continues to refine its technology, the focus will remain on establishing a new standard of care for sepsis management, potentially disrupting the current market for infectious disease therapeutics and diagnostic tools.
See full PATH EX company page
